Business
Lineage Cell Therapeutics Announces Updates to the 3rd Annual Spinal Cord Injury Investor Symposium
CARLSBAD, Calif., June 05, 2025--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel allogeneic, or "off the shelf", cell therapies for serious neurological and ophthalmic conditions, today announced additional presenters to the 3rd Annual Spinal Cord Injury Investor Symposium ("3rd SCIIS"). The 3rd SCIIS will be a fully virtual event, with interactive and on-demand sessions available starting on June 27, 2025.
About this update from Lineage Cell Therapeutics, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1740,"height":360,"url":"https://media.zenfs.com/en/business-wire.com/ae830cdb9752907224c9d55246d0df63"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/DnrtbW8.4NYkyU9SByYMKg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTE5OTtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/ae830cdb9752907224c9d55246d0df63","width":960,"height":199},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/D5LbNg4k80dMSg_Lgr9Pow--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD00OTY7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/ae830cdb9752907224c9d55246d0df63","width":1200,"height":248}},"lazy":false},{"type":"text","content":"Fully Virtual Event Scheduled for June 27, 2025","length":47,"tagName":"p","attribs":{}},{"type":"text","content":"CARLSBAD, Calif., June 05, 2025--(BUSINESS WIRE)--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel allogeneic, or "off the shelf", cell therapies for serious neurological and ophthalmic conditions, today announced additional presenters to the 3rd Annual Spinal Cord Injury Investor Symposium ("3rd SCIIS"). The 3rd SCIIS will be a fully virtual event, with interactive and on-demand sessions available starting on June 27, 2025.","length":519,"tagName":"p"},{"type":"text","content":""We are excited by the incredible response by presenters that have confirmed to date and believe that our third symposium will offer attendees the most comprehensive and relevant discussions related to the field of spinal cord injury we have been able to assemble to date," stated Brian M. Culley, Lineage CEO. "We believe collaborative problem-solving is an integral component to the goal of supporting individuals living with SCI and we are proud to bring together a diverse and broad array of clinical and preclinical companies, thought leader perspectives, and most importantly, insights from persons with lived experience. This event will be open and accessible online at no cost, and we invite you to register directly through the symposium website and to join us for the virtual event on June 27th as we again assemble a unique group of forward-thinking leaders in SCI product development."","length":917,"tag...